Clinical trial
Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes…
NCT00330330 · Ionis Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00330330 |
|---|---|
| Title | Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment |
| Official title | A Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Activity of ISIS 113715 in Patients With Type 2 Diabetes Mellitus Who Have Not Received Prior Therapy |
| Lead sponsor | Ionis Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | ISIS 113715 |
| Enrollment | 96 |
| Start date | Feb 1, 2003 |
| Completion | Aug 1, 2006 |
| First posted | May 26, 2006 |
| Last update posted | Feb 6, 2008 |
| Countries | Poland, Russia |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: